Dosing Begins in Phase 1 Trial of INV-102, Potential PWS Therapy

Dosing Begins in Phase 1 Trial of INV-102, Potential PWS Therapy

306257

Dosing Begins in Phase 1 Trial of INV-102, Potential PWS Therapy

The first healthy volunteers were dosed in a Phase 1 clinical trial evaluating Inversago Pharma‘s INV-102, a potential therapy for Prader-Willi syndrome (PWS) and other metabolic disorders. According to a company press release, the trial, underway in Canada, started dosing following a “No Objection Letter” from Health Canada. The study intends to evaluate the therapy’s safety, tolerability and pharmacokinetics — how it moves into, through, and out of the body. INV-102 is a next-generation small molecule…

You must be logged in to read/download the full post.